Endo International Stock Analysis (NASDAQ:ENDP)

Add to My Stocks
$10.29 $0.19 (1.81%) ENDP stock closing price Apr 21, 2017 (Closing)
Watch Robo Advisor Video of ENDP Stock Analysis
Endo International
Updated on : Apr 21, 2017
previous close
ENDP 10.3 (0%)
S&P 500 2348.7 (0%)
Closing Price On: Apr 21, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Drugs
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2016-Q4
$million
%
YOY GROWTH
Compared to the industry
Operating Profit
Operating Margin:
-86.6%
Sector Average:
0.6%
5 Quarter Net Profit
Net Margins
2016-Q4
%
LTM Margin
Debt/Equity Ratio
Debt:
8.27B
Debt/Equity Ratio:
 3.06
Compared to the industry
Cash Flow
Operating cash flow:
$81.1M
Net Income:
-$3.34B
PROS      CONS
Recent Growth
PE Valuation
PS Valuation
Operating Margins
Net Margins
High Debt Burden
ROIC
ROE
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
ENDP PS :
0.6
Industry PS :
4.6
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Invested Capital:
-21.1%
Return on Equity:
-62.2%
Free Cash Flow Margin:
2.8%
Double Tap To Exit Full Screen
0:00
/

Endo International Analysis Video

271 6 2

View Endo International stock analysis video. This is our ENDP analyst opinion covering the buy and sell arguments for ENDP stock.

Endo International plc - Ordinary Shares Stock Rating (2.7/5)

Our Endo International stock opinion is based on fundamentals of the company. This Endo International stock analysis is based on latest Q4 earnings for 2016. The stock price analysis takes into account a company's valuation metrics.

Should you buy ENDP stock?

  • The Year Over Year (YoY) revenue growth for Endo International was 15.6% in 2016 Q4.
  • ENDP stock is trading at an earnings multiple of 2.2 which is better than the industry average of 21.5.
  • The lower PS ratio 0.6 for ENDP stock versus Medical-Drugs industry average of 4.6 is a positive for the company.

Should you sell ENDP stock?

  • Over the last twelve months, Endo International posted an average operating loss margin of -86.6%.
  • Over the last 12 months, Endo International had an average Net loss of -83.5%.
  • With a debt/equity ratio of  3.06, Endo International is highly leveraged in comparison to Medical peers.
  • The company has a negative Return on Invested Capital of -21.1%, which is a red flag.
  • A negative ROE of -62.2% indicates that the company is not able to generate profits with the money shareholders have invested.

Comments on this video and Endo International stock